Canada-based venture capital firm AgeChem led the B round, which included participation by existing investors Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.
Conatus Pharmaceuticals, a liver disease healthcare company, has raised $20m in an initial close of its series B round from a consortium including Switzerland-based drugs company F Hoffman-La Roche’s corporate venturing unit.
Canada-based venture capital firm AgeChem led the B round, which included participation by existing investors Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.
Conatus will use the proceeds to advance the clinical development of CTS-1027, a phase II-stage drug candidate the…
